By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Koningin Wilhelminalaan 22

Driebergen    3972 EX  The Netherlands
Phone: 31-655-764-221 Fax:


Company News
Merus Completes Acquisition Of Elantan, Isoket And Deponit Rights From UCB And Announces Date Of Q1 2016 Earnings Release 2/5/2016 6:47:08 AM
Merus Snags Three Cardiovascular Products from UCB Group (UCBJF.PK) in EUR 92 Million Deal 2/2/2016 6:08:49 AM
Merus And Gustave Roussy Form Strategic Collaboration To Develop Innovative Bispecific Antibodies For Therapeutic Immuno-Oncology Applications 1/4/2016 7:10:20 AM
Merus Reports Fiscal 2015 Results And Provides Business Update 12/8/2015 8:39:00 AM
Merus To Host Conference Call On Year End Results 12/2/2015 7:46:10 AM
Merus Announces Final Ruling In Inequitable Conduct Case Against Regeneron (REGN) 11/4/2015 7:11:20 AM
Merus Banks 72.8 Million Euro Series C 8/26/2015 6:32:31 AM
Merus Prevails in Inequitable Conduct Case Against Regeneron (REGN) 8/10/2015 9:09:27 AM
Merus Appoints Mark Iwicki As President Of The Supervisory Board 6/1/2015 10:09:47 AM
Novartis Pharma AG (NVS) Unloads Certain Specialty Product Rights to Merus for $29.5 Million 5/22/2015 5:19:32 AM